Anti-TNF | ||||||
---|---|---|---|---|---|---|
All | ETA | INF | ADA | GOL | TOC | |
In patients without evidence of latent tuberculosis infection | ||||||
(n = 3568) | (n = 655) | (n = 448) | (n = 920) | (n = 676) | (n = 869) | |
Duration of follow-up (days), median (IQR) | 553 (227–1050) | 629 (253–1196) | 583 (216–1161) | 510 (216–925) | 470 (203–958) | 608 (271–1061) |
Person-years | 6421.3 | 1295.9 | 844.4 | 1549.0 | 1113.1 | 1618.9 |
Case of TB, n | 34 | 4 | 10 | 9 | 6 | 5 |
Rate/100,000 person-years (95% CI) | 529.5 (370.9–727.9) | 308.7 (95.8–717.0) | 1184.2 (593.4–2077.9) | 581.0 (279.2–1047.3) | 539.0 (214.2–1092.2) | 308.9 (110.7–663.8) |
Adjusted IRRa | 1.00 (ref) | 3.65 (1.14–11.7) | 2.18 (0.66–7.14) | 2.00 (0.56–7.16) | 1.07 (0.29–4.04) | |
In patients who were treated for latent tuberculosis infection before biologic therapy | ||||||
(n = 1168) | (n = 279) | (n = 113) | (n = 298) | (n = 182) | (n = 296) | |
Duration of follow-up (days), median (IQR) | 612 (248–1134) | 680 (257–1315) | 803 (271–1230) | 506 (221–963) | 549 (213–1144) | 668 (304–1066) |
Person-years | 2229.5 | 583.8 | 242.7 | 501.9 | 334.3 | 566.8 |
Case of TB, n | 14 | 3 | 3 | 3 | 0 | 5 |
Rate/100,000 person-years (95% CI) | 627.9 (353.7–1016.6) | 513.9 (127.8–1332.0) | 1236.2 (307.4–3204.4) | 597.7 (148.6–1549.4) | _ | 882.2 (316.3–1896.0) |
Adjusted IRR | 1.00 (ref) | 2.54 (0.50–12.96) | 0.93 (0.18–4.70) | _ | 1.35 (0.32–5.80) |